Rituximab in pathologically confirmed sarcoidosis affecting the central nervous system: a multi-center retrospective study
{{output}}
Background: Rituximab, a monoclonal antibody that depletes B cells by targeting CD20, has been suggested as a treatment option for neurosarcoidosis, but evidence to support its use is limited. ... ...
